Woodline Partners
MCRB icon

Woodline Partners’s Seres Therapeutics MCRB Stock Holding History

Woodline Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-102,294
Closed -$1.58M – 625
2024
Q1 		$1.58M Buy
102,294
+37,780
+59% +$815K 0.01% 441
2023
Q4 		$1.81M Buy
64,514
+54,514
+545% +$1.43M 0.02% 384
2023
Q3 		$476K Sell
10,000
-2,180
-18% -$166K 0.01% 499
2023
Q2 		$1.17M Buy
+12,180
New +$1.33M 0.01% 472

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Woodline Partners's MCRB Position: Q2 2024 in Review

Woodline Partners sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 102,294 shares — an estimated $1.58M sold.

Woodline Partners first reported a position in MCRB in Q2 2023 and held it in 4 quarters. The position peaked at $1.81M in Q4 2023. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • Woodline Partners reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Woodline Partners sold 102,294 Seres Therapeutics shares in Q2 2024, an estimated $1.58M.
  • Woodline Partners first reported a position in Seres Therapeutics in Q2 2023 and held it in 4 quarters.
  • Woodline Partners's Seres Therapeutics position peaked at $1.81M in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.